Abiopharma

🔍 JACKSON JOHN EARL (Executive)

Company: Main Street Capital CORP (MAIN)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Acquired 96 shares of Common Stock at $52.02 per share (Direct)
  Date: 2026-06-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 84,498.94 | transaction_form_type: 5 | Footnotes: F1
• Acquired 250 shares of Common Stock at $51.29 per share (Direct)
  Date: 2026-06-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 84,748.72 | transaction_form_type: 5 | Footnotes: F1
• Acquired 114 shares of Common Stock at $51.01 per share (Direct)
  Date: 2026-06-29 | Code: J | equity_swap_involved: 0 | shares_owned_after: 84,862.70 | transaction_form_type: 5 | Footnotes: F1
• Acquired 288 shares of Common Stock at $51.56 per share (Direct)
  Date: 2026-06-29 | Code: J | equity_swap_involved: 0 | shares_owned_after: 85,150.85 | transaction_form_type: 5 | Footnotes: F1
• Acquired 97 shares of Common Stock at $53.09 per share (Direct)
  Date: 2026-07-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 85,248.16 | transaction_form_type: 5 | Footnotes: F1
• Acquired 247 shares of Common Stock at $53.41 per share (Direct)
  Date: 2026-07-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 85,495.31 | transaction_form_type: 5 | Footnotes: F1
• Acquired 10 shares of Common Stock at $52.18 per share (Direct)
  Date: 2026-06-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 2,036.00 | transaction_form_type: 5 | Footnotes: F1
• Acquired 10 shares of Common Stock at $53.47 per share (Direct)
  Date: 2026-07-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 2,046.00 | transaction_form_type: 5 | Footnotes: F1

Footnotes:

• F1: The reporting person acquired these shares under a dividend reinvestment plan, pursuant to a dividend reinvestment transaction exempt from Section 16 under Rule 16a-11.